CORPORATE WORLD

Glenmark Pharma launches pulmonary fibrosis treatment drug in India

Agency,
14/10/2020   0 Comments

Glenmark Pharma on Wednesday announced the launch of its generic version of Nintedanib (NINDANIB), used for the treatment of pulmonary fibrosis, in India.

 
"Glenmark being a leader in the area of respiratory has been amongst the first to launch the branded generic version at an affordable cost for the treatment of pulmonary fibrosis in India, it said in a regulatory filing.
 
This will provide patients a far more cost effective treatment option, and enable doctors to treat a wider patient population in the country, it added.
 
Glenmark said Nintedanib is approved by the Indian drug regulator for the treatment of Idiopathic (unknown cause) Pulmonary Fibrosis (IPF).

WRITE A COMMENT

...
Sign in with
Or procced without registration